New modules to expand processing capabilities of the CliniMACS Prodigy® Platform: electroporation and final formulation.

August 19, 2025

The CliniMACS Prodigy® represents the next generation in automated cell processing, offering advanced integrated solutions to streamline cell processing workflows – from cell separation through cell culture to formulation of...

New automated process to simplify the manufacturing of gene-engineered Natural Killer Cells and Clinical-grade Tumor-Reactive T cell

August 19, 2025

CAR-engineered NK cells represent a breakthrough in cancer immunotherapy, offering a host of advantages. These include multiple cytotoxicity mechanisms, a decreased risk of graft-versus-host disease (GVHD) in allogeneic scenarios, and...

New automated process to simplify the manufacturing of gene-engineered Natural Killer Cells and Clinical-grade Tumor-Reactive T cell

June 06, 2024

CAR-engineered NK cells represent a breakthrough in cancer immunotherapy, offering a host of advantages. These include multiple cytotoxicity mechanisms, a decreased risk of graft-versus-host disease (GVHD) in allogeneic scenarios, and...

Myltenyi Biotech – New modules to expand processing capabilities of the CliniMACS Prodigy® Platform: electroporation and final formulation.

June 20, 2023